ERYTECH Pharma develops ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs.
Its first product reported positive Phase III results of its pivotal study in Acute Lymphoblastic Leukemia (ALL) in Europe and is in four other clinical programs : a Phase IIb study in Acute Myeloid Leukemia (AML) , a Phase II study in pancreatic cancer and an Expanded Access program in ALL in Europe, and a Phase I/II study in ALL in the USA.
ERYTECH proprietary technology is based on encapsulation of therapeutic compounds into red blood cells.
The company has a production unit located in Lyon with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements, one with Orphan Europe (Recordati) and one with Teva.
ERYTECH today announced that Gil Beyen, Chairman and Chief Executive Officer and Eric Soyer, Chief Financial Officer and Chief Operating Officer, will present at the 18th Annual BIO CEO and Investor Conference being held February 8-9, 2016 and the Leerink Partners 5th Annual Global Healthcare Conference being held February 10-11, 2016. Both conferences are being held at the Waldorf Astoria Hotel in New York.
ERYTECH reports revenue and cash balance for the fourth quarter of 2015.
ERYTECH announces that an independent Data and Safety Monitoring Board (DSMB) completed its third safety assessment of the company’s Phase 2b ENFORCE 1 study in acute myeloid leukemia (AML) and that enrollment will continue until completion.
ERYTECH today announced that Yann Godfrin will be leaving the company to pursue new entrepreneurial projects.
ERYTECH Pharma makes 3 poster presentations at ASH annual meeting 2015
ERYTECH pharma attends Qualified Person Forum 2015 from November 24-26 in Berlin, Germany.
ERYTECH Pharma takes part in ESMO Symposium Immuno-Oncology 2015 on November 20-21, 2015, in Lausanne, Switzerland.
FINANCE – ERYTECH attends Actionaria at Palais des congrès, Paris (booth C20 Hall Maillot niv.2) on November 20 and 21st, 2015.